Sequenom's Q2 Revenues Rise 17 Percent as It Names T21 Test

The firm reported sales growth for both its genetic analysis products and for its diagnostic services. It also reiterated plans for the T21 test, which has been named MaterniT21.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories